[Insulin sensitivity in NIDDM patients with normo- and microalbuminuria].

Wiad Lek

I Oddziału Chorób Wewnetrznych Szpitala Górniczego w Zabrzu.

Published: February 1999

There is contradictory information relating to insulin sensitivity in NIDDM patients with microalbuminuria. The numerous clinical and epidemiological investigations have revealed a greater insulin resistance in these patients. However on the ground of the Nielsen and co-workers observations it has been ascertained that the level of insulin sensitivity is similar in exactly selected NIDDM patients with normo- and microalbuminuria. It suggests, that the increased cardiovascular morbidity and mortality among microalbuminuric NIDDM patients may not primarily be a consequence of more pronounced levels of hyperinsulinemia or insulin resistance. The influence of environmental factors may aggravate resident insulin resistance, elevate albuminuria, and may cause itself an increased cardiovascular risk.

Download full-text PDF

Source

Publication Analysis

Top Keywords

niddm patients
16
insulin resistance
12
sensitivity niddm
8
patients normo-
8
insulin sensitivity
8
increased cardiovascular
8
patients
5
insulin
5
[insulin sensitivity
4
niddm
4

Similar Publications

Background: Diabetes mellitus is a growing global health issue, especially in low- and middle-income countries like Ethiopia. To the best of our knowledge, the impact of diabetes knowledge on glycemic control in Ethiopia has not been documented. This study assessed diabetes knowledge and its relationship with glycemic control among Type 2 diabetes (T2DM) patients in Debre Berhan, Ethiopia.

View Article and Find Full Text PDF

Cardiovascular Outcomes in Patients with Complex Type 2 Diabetes Mellitus Treated with the Dual SGLT Inhibitor Sotagliflozin: A Meta-analysis.

Diabetes Ther

January 2025

The State Key Laboratory Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.

Introduction: Scientific publications have shown sodium-glucose co-transporter-2 (SGLT2) inhibitors to have several beneficial effects in patients with complex type 2 diabetes mellitus (T2DM). However, sodium-glucose co-transporter-1 (SGLT-1) inhibitor is still under investigation in clinical trials. Recently, a dual inhibitor of sodium-glucose co-transporter (SGLT1/2), sotagliflozin, has been approved for use in patients with T2DM.

View Article and Find Full Text PDF

Purpose: To compare the amplitudes and implicit times of the oscillatory (OPs) of the full-field electroretinograms (ERGs) to those of the 30 Hz flicker ERGs in differentiating eyes with diabetic retinopathy (DR) from normal eyes.

Study Design: Single-center observational study.

Methods: Full-field ERGs were recorded in 55 patients with Type 2 diabetes mellitus (DM) and 20 normal control subjects.

View Article and Find Full Text PDF

Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been added to the mainstay of treatment for chronic heart failure. Recent studies suggest that empagliflozin may also reverse cardiac remodeling in heart failure by reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. In our study, we wanted to show the decrease in NT-proBNP levels, which is an indicator of poor prognosis in heart failure, and to see if there was a decrease in the rate of renal progression in patients with HF after empagliflozin use.

View Article and Find Full Text PDF

Background: Glecaprevir/pibrentasvir is an effective antiviral therapy for hepatitis C virus infection and is generally regarded safe in patients with renal impairment. However, renal complications are a notable, albeit rare, concern.

Case Presentation: We report a case of acute kidney injury in a man in his 50s with chronic hepatitis C virus, chronic obstructive pulmonary disease, morbid obesity, a history of heroin dependence, and untreated type 2 diabetes mellitus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!